ABIONYX Pharma SA (0RAG.L)
| Previous close | 1.3441 |
| Open | 0.0000 |
| Bid | 0.0000 x N/A |
| Ask | 0.0000 x N/A |
| Day's range | 0.0000 - 0.0000 |
| 52-week range | |
| Volume | |
| Avg. volume | 2,240 |
| Market cap | 294,587 |
| Beta (5Y monthly) | 0.17 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
ABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company’s Share Capital
PARIS, December 04, 2023--Regulatory News: ABIONYX Pharma (Paris:ABNX):
- Business Wire
ABIONYX Pharma presents preclinical results for CER-001 in Brain Fog, at the 1st International Scientific Congress on Brain-Kidney Interaction in Naples on November 23-24, 2023
TOULOUSE, France & LAKELAND, Mich., November 23, 2023--Regulatory News: ABIONYX Pharma, (FR0012616852 – ABNX – PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies based on the world’s only natural recombinant apoA-I, announces the presentation of new preclinical data for CER-001 in the treatment of brain dysfunction associated with acute kidney injury at the 1st International Congress on brain-kidney interaction: from physiology
- Business Wire
ABIONYX Pharma announces new positive results in a uveitis model for the strategic development of the first class of biomedicines in ophthalmology based on its recombinant apoA-I
TOULOUSE, France & LAKELAND, Mich., November 21, 2023--Regulatory News: ABIONYX Pharma, (FR0012616852 - ABNX - PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies based on the world's only recombinant human apoA-1, announces new positive results in ophthalmology for the first class of CER-001-based biomedicines for the treatment of ocular pathologies, and the appointment of Mr. Jérôme Martinez as ABIONYX Pharma's Senior Advisor i
